Published in J Urol on June 15, 2012
Recent advances in ureteral tissue engineering. Curr Urol Rep (2015) 0.88
Tissue engineering in animal models for urinary diversion: a systematic review. PLoS One (2014) 0.82
Ureter regeneration-the proper scaffold has to be defined. PLoS One (2014) 0.79
Artificial urinary conduit construction using tissue engineering methods. Cent European J Urol (2014) 0.78
Transplantation of autologous minced bladder mucosa for a one-step reconstruction of a tissue engineered bladder conduit. Biomed Res Int (2013) 0.77
Visualisation of newly synthesised collagen in vitro and in vivo. Sci Rep (2016) 0.75
The promises and challenges of tissue engineering for urinary diversion. J Urol (2012) 0.75
Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat Genet (2009) 6.91
Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol (2006) 5.02
Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. Nat Genet (2010) 2.96
Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. Blood (2010) 2.31
Indium-111-labeled girentuximab immunoSPECT as a diagnostic tool in clear cell renal cell carcinoma. Eur Urol (2013) 2.04
Circulating tumour tissue fragments in patients with pulmonary metastasis of clear cell renal cell carcinoma. J Pathol (2009) 1.96
Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther (2013) 1.89
Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. Eur Urol (2010) 1.86
Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma. Oncogene (2004) 1.67
Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models. J Nucl Med (2005) 1.57
Expression of HIF-1alpha, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer. Lung Cancer (2005) 1.48
Pharmacokinetics and toxicity of intravesical TMX-101: a preclinical study in pigs. BJU Int (2011) 1.42
Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results from The Netherlands cohort study. BMC Cancer (2005) 1.41
Immunotherapy for renal cell carcinoma. Eur Urol (2003) 1.32
PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer. J Immunother (2012) 1.32
Heparanase is essential for the development of diabetic nephropathy in mice. Diabetes (2011) 1.29
Aminopeptidase A is a functional target in angiogenic blood vessels. Cancer Cell (2004) 1.28
PET radioimmunoscintigraphy of renal cell cancer using 89Zr-labeled cG250 monoclonal antibody in nude rats. Cancer Biother Radiopharm (2004) 1.21
Induction of glomerular heparanase expression in rats with adriamycin nephropathy is regulated by reactive oxygen species and the renin-angiotensin system. J Am Soc Nephrol (2006) 1.19
Longer than expected-duration of caudal analgesia with two different doses of levobupivacaine in children undergoing hypospadias repair. J Pediatr Urol (2010) 1.17
Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re. J Nucl Med (2004) 1.11
PET of hypoxia with 89Zr-labeled cG250-F(ab')2 in head and neck tumors. J Nucl Med (2010) 1.11
Overexpression of carbonic anhydrase IX (CAIX) is an independent unfavorable prognostic marker in endometrioid ovarian cancer. Virchows Arch (2011) 1.10
Anti-renal cell carcinoma chimeric antibody G250: cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity. Cancer Immunol Immunother (2002) 1.08
Genetic and epigenetic alterations in the von hippel-lindau gene: the influence on renal cancer prognosis. Clin Cancer Res (2008) 1.06
Lack of efficacy of two consecutive treatments of radioimmunotherapy with 131I-cG250 in patients with metastasized clear cell renal cell carcinoma. J Clin Oncol (2005) 1.05
Colocalization of carbonic anhydrase 9 expression and cell proliferation in human head and neck squamous cell carcinoma. Clin Cancer Res (2005) 1.01
Carbonic anhydrase IX in early-stage non-small cell lung cancer. Clin Cancer Res (2004) 1.00
Prognostic impact of carbonic anhydrase IX expression in human renal cell carcinoma. BJU Int (2007) 0.97
Radioimmunotherapy with [131I]cG250 in patients with metastasized renal cell cancer: dosimetric analysis and immunologic response. Clin Cancer Res (2005) 0.97
A common variant at 8q24.21 is associated with renal cell cancer. Nat Commun (2013) 0.96
Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study. J Immunother (2002) 0.95
Elevated CAIX Expression is Associated with an Increased Risk of Distant Failure in Early-Stage Cervical Cancer. Biomark Insights (2008) 0.94
Residualizing iodine markedly improved tumor targeting using bispecific antibody-based pretargeting. J Nucl Med (2005) 0.94
Preliminary analysis of patients with progressive renal cell carcinoma vaccinated with CA9-peptide-pulsed mature dendritic cells. J Immunother (2007) 0.93
Targeting of metastatic renal cell carcinoma with the chimeric monoclonal antibody G250 labeled with (131)I or (111)In: an intrapatient comparison. Clin Cancer Res (2003) 0.93
111In-bevacizumab imaging of renal cell cancer and evaluation of neoadjuvant treatment with the vascular endothelial growth factor receptor inhibitor sorafenib. J Nucl Med (2010) 0.92
The effect on pain experienced by male patients of watching their office-based flexible cystoscopy. BJU Int (2008) 0.92
Targeted therapy of renal cell carcinoma: synergistic activity of cG250-TNF and IFNg. Int J Cancer (2009) 0.92
Expression and activity of carbonic anhydrase IX is associated with metabolic dysfunction in MDA-MB-231 breast cancer cells. Cancer Invest (2009) 0.92
Localization and functional characterization of glycosaminoglycan domains in the normal human kidney as revealed by phage display-derived single chain antibodies. J Am Soc Nephrol (2005) 0.92
Antibody inhibiting enzymatic activity of tumour-associated carbonic anhydrase isoform IX. Eur J Pharmacol (2011) 0.91
Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma. Eur Urol (2012) 0.91
Antibody-specific detection of CAIX in breast and prostate cancers. Biochem Biophys Res Commun (2009) 0.90
Carotenoid and vitamin intake, von Hippel-Lindau gene mutations and sporadic renal cell carcinoma. Cancer Causes Control (2007) 0.90
Dosimetric analysis of 177Lu-cG250 radioimmunotherapy in renal cell carcinoma patients: correlation with myelotoxicity and pretherapeutic absorbed dose predictions based on 111In-cG250 imaging. J Nucl Med (2011) 0.90
Th1-polarizing capacity of clinical-grade dendritic cells is triggered by Ribomunyl but is compromised by PGE2: the importance of maturation cocktails. J Immunother (2005) 0.90
Hypertension, antihypertensives and mutations in the Von Hippel-Lindau gene in renal cell carcinoma: results from the Netherlands Cohort Study. J Hypertens (2005) 0.90
Pretargeting with labeled bivalent peptides allowing the use of four radionuclides: (111)In, (131)I, (99m)Tc, and (188)Re. Clin Cancer Res (2003) 0.89
Applicability of a disposable home urinary flow measuring device as a diagnostic tool in the management of males with lower urinary tract symptoms. Urol Int (2012) 0.88
Targeting of adenovirus to human renal cell carcinoma cells. Urology (2003) 0.88
Recent advances in ureteral tissue engineering. Curr Urol Rep (2015) 0.88
Long-term outcomes in males with disorders of sex development. J Urol (2013) 0.87
The prognostic value of endogenous hypoxia-related markers for head and neck squamous cell carcinomas treated with ARCON. Radiother Oncol (2006) 0.87
Role of complex cadherins in cell-cell adhesion evaluated by spheroid formation in renal cell carcinoma cell lines. Oncol Rep (2004) 0.87
Urethral reconstruction of critical defects in rabbits using molecularly defined tubular type I collagen biomatrices: key issues in growth factor addition. Tissue Eng Part A (2010) 0.86
Experimental rat bladder urothelial cell carcinoma models. World J Urol (2009) 0.85
A synthetic glycosaminoglycan mimetic (RGTA) modifies natural glycosaminoglycan species during myogenesis. J Cell Sci (2005) 0.85
ImmunoPET imaging of renal cell carcinoma with (124)I- and (89)Zr-labeled anti-CAIX monoclonal antibody cG250 in mice. Cancer Biother Radiopharm (2013) 0.85
Pharmacokinetics and tumor targeting of 131I-labeled F(ab')2 fragments of the chimeric monoclonal antibody G250: preclinical and clinical pilot studies. Cancer Biother Radiopharm (2004) 0.85
Better effect of sorafenib on the rhabdoid component of a clear cell renal cell carcinoma owing to its higher level of vascular endothelial growth factor-A production. Histopathology (2011) 0.85
In-vivo performance of high-density collagen gel tubes for urethral regeneration in a rabbit model. Biomaterials (2012) 0.84
Prognostic value of carbonic anhydrase IX and Ki-67 expression in squamous cell carcinoma of the tongue. Jpn J Clin Oncol (2007) 0.84
Radiolabeled antibodies in renal cell carcinoma. Cancer Imaging (2007) 0.84
Potential role of genetic markers in the management of kidney cancer. Eur Urol (2012) 0.84
Application of monoclonal antibody G250 recognizing carbonic anhydrase IX in renal cell carcinoma. Int J Mol Sci (2013) 0.84
Improving the cell distribution in collagen-coated poly-caprolactone knittings. Tissue Eng Part C Methods (2012) 0.83
Comparison of IgG and F(ab')2 fragments of bispecific anti-RCCxanti-DTIn-1 antibody for pretargeting purposes. Eur J Nucl Med Mol Imaging (2005) 0.83
Tissue engineering of diseased bladder using a collagen scaffold in a bladder exstrophy model. BJU Int (2014) 0.82
Interferons can upregulate the expression of the tumor associated antigen G250-MN/CA IX, a potential target for (radio)immunotherapy of renal cell carcinoma. Cancer Biother Radiopharm (2003) 0.82
Microscale mechanical properties of single elastic fibers: the role of fibrillin-microfibrils. Biomaterials (2009) 0.82
Pretargeting of carcinoembryonic antigen-expressing tumors with a biologically produced bispecific anticarcinoembryonic antigen x anti-indium-labeled diethylenetriaminepentaacetic acid antibody. Clin Cancer Res (2005) 0.81
Targeting of biliary cancer with radiolabeled chimeric monoclonal antibody CG250. Cancer Biother Radiopharm (2006) 0.81
Tyrosine kinase inhibitor sorafenib decreases 111In-girentuximab uptake in patients with clear cell renal cell carcinoma. J Nucl Med (2014) 0.81
Lyophilisomes as a new generation of drug delivery capsules. Int J Pharm (2012) 0.81
Evaluation of an orthotopic rat bladder urothelial cell carcinoma model by cystoscopy. BJU Int (2008) 0.80
Zero echo time magnetic resonance imaging of contrast-agent-enhanced calcium phosphate bone defect fillers. Tissue Eng Part C Methods (2013) 0.80
Tumor antigens and markers in renal cell carcinoma. Urol Clin North Am (2003) 0.80
Renal cell carcinoma-associated G250 methylation and expression: in vivo and in vitro studies. Urology (2002) 0.80
Dual contrast agent for computed tomography and magnetic resonance hard tissue imaging. Tissue Eng Part C Methods (2012) 0.79
Seamless vascularized large-diameter tubular collagen scaffolds reinforced with polymer knittings for esophageal regenerative medicine. Tissue Eng Part C Methods (2014) 0.79
Preclinical imaging in bone tissue engineering. Tissue Eng Part B Rev (2014) 0.79
Is there a need for smooth muscle cell transplantation in urethral reconstruction? Tissue Eng Part A (2014) 0.79
In vivo-targeted gene delivery using antibody-based nonviral vector. Hum Gene Ther (2002) 0.79
Preferred mesh-based inguinal hernia repair in a teaching setting: results of a randomized study. Arch Surg (2004) 0.78
Pattern of CAIX expression is prognostic for outcome and predicts response to ARCON in patients with laryngeal cancer treated in a phase III randomized trial. Radiother Oncol (2013) 0.78
Ureteral tissue engineering: where are we and how to proceed? Tissue Eng Part B Rev (2013) 0.78
Effect of tyrosine kinase inhibitor treatment of renal cell carcinoma on the accumulation of carbonic anhydrase IX-specific chimeric monoclonal antibody cG250. BJU Int (2011) 0.78
Tailored doxorubicin-hyaluronan conjugate as a potent anticancer glyco-drug: an alternative to prodrug approach. Macromol Biosci (2013) 0.78
Body mass index and von Hippel-Lindau gene mutations in clear-cell renal cancer: Results of the Netherlands Cohort Study on diet and cancer. Ann Epidemiol (2010) 0.78
Urgent-SQ implant in treatment of overactive bladder syndrome: 9-year follow-up study. Neurourol Urodyn (2012) 0.77
Polymorphisms in genes related to activation or detoxification of carcinogens might interact with smoking to increase renal cancer risk: results from The Netherlands Cohort Study on diet and cancer. World J Urol (2007) 0.77
Intra-uterine tissue engineering of full-thickness skin defects in a fetal sheep model. Biomaterials (2010) 0.77
Molecular imaging and carbonic anhydrase IX-targeted radioimmunotherapy in clear cell renal cell carcinoma. Immunotherapy (2013) 0.77
Renal cell carcinoma-associated antigen G250 encodes a naturally processed epitope presented by human leukocyte antigen-DR molecules to CD4(+) T lymphocytes. Int J Cancer (2002) 0.76
Optimizing lutetium 177-anti-carbonic anhydrase IX radioimmunotherapy in an intraperitoneal clear cell renal cell carcinoma xenograft model. Mol Imaging (2014) 0.76